drugset

Drugs / D097

Follow last change Mar 2024 re-read 2 minutes ago

D097

Investigated by: Chong Kun Dang Pharmaceutical

Trials 8 · a red edge is where a trial was stopped

today NCT06112678 · Ph 1 NCT05749861 · Ph 1 NCT05549401 · Ph 1 NCT05192356 · Ph 1 NCT04883658 · Ph 1 NCT04660370 · Ph 1 NCT04587206 · Ph 1 NCT04258865 · Ph 1

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06112678	Jan → Feb 2024	hyperlipidemia, hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT05749861	Apr → Jun 2023	hyperlipidemia, combined, 2	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT05549401	Sep → Nov 2022	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT05192356	Feb → May 2022	hyperlipidemia, combined, 2	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT04883658	Jun → Jul 2021	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT04660370	Jan → Feb 2021	hyperlipidemia, combined, 2	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT04587206	Oct → Dec 2020	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT04258865	Mar → Apr 2020	hyperlipidemia, hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04304547 Comparator	Feb → Apr 2020	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

Field	Value	Cited text
Known as	D097	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06112678 ↗ 8 NCT04587206 ↗ NCT04258865 ↗ NCT04660370 ↗ NCT04883658 ↗ NCT05549401 ↗ NCT05749861 ↗ NCT05192356 ↗ NCT04304547 ↗
Route	Oral	“QD, PO” NCT04258865 ↗